Scarica l'app Stockscreener
138.50
0.51%
0.70
Dopo l'orario di chiusura:
138.50
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$137.80
Aprire:
$137.55
Volume 24 ore:
7.12M
Relative Volume:
0.65
Capitalizzazione di mercato:
$232.32B
Reddito:
$175.96B
Utile/perdita netta:
$18.10B
Rapporto P/E:
14.95
EPS:
9.2638
Flusso di cassa netto:
$38.28B
1 W Prestazione:
+0.26%
1M Prestazione:
+2.43%
6M Prestazione:
+27.10%
1 anno Prestazione:
+42.53%
Intervallo 1D:
$136.57
$138.85
Intervallo di 1 settimana:
$133.87
$138.85
Portata 52W:
$93.66
$147.96
Citigroup Inc Stock (C) Company Profile
Nome
Citigroup Inc
Settore
Industria
Telefono
(212) 559-1000
Indirizzo
388 GREENWICH STREET, NEW YORK, NY
Compare C vs JPM, BAC, HSBC, RY, WFC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
C
Citigroup Inc
|
138.50 | 231.15B | 175.96B | 18.10B | 38.28B | 9.2638 |
JPM
Jpmorgan Chase Co
|
353.56 | 942.89B | 297.42B | 64.78B | 148.32B | 23.34 |
BAC
Bank Of America Corp
|
62.56 | 438.24B | 194.43B | 33.77B | 64.54B | 4.3483 |
HSBC
Hsbc Holdings Plc Adr
|
103.70 | 359.98B | 133.80B | 21.76B | 105.99B | 6.0511 |
RY
Royal Bank Of Canada
|
205.98 | 286.31B | 99.69B | 16.04B | 26.84B | 11.15 |
WFC
Wells Fargo Co
|
89.45 | 271.16B | 128.92B | 22.97B | -2.35B | 6.8796 |
Citigroup Inc Stock (C) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-26 | Iniziato | Jefferies | Buy |
| 2025-12-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-05-15 | Iniziato | TD Cowen | Hold |
| 2025-01-06 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2024-12-03 | Aggiornamento | Keefe Bruyette | Mkt Perform → Outperform |
| 2024-04-04 | Reiterato | Evercore ISI | In-line |
| 2024-03-25 | Reiterato | Wells Fargo | Overweight |
| 2024-03-14 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-02-14 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-01-30 | Aggiornamento | Morgan Stanley | Underweight → Overweight |
| 2024-01-10 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-01-09 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-01-08 | Downgrade | Societe Generale | Hold → Sell |
| 2024-01-03 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2023-12-18 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2023-09-07 | Iniziato | HSBC Securities | Hold |
| 2023-07-18 | Aggiornamento | Odeon | Hold → Buy |
| 2023-07-10 | Downgrade | Societe Generale | Buy → Hold |
| 2022-12-08 | Iniziato | Piper Sandler | Neutral |
| 2022-10-03 | Downgrade | Goldman | Buy → Neutral |
| 2022-09-06 | Downgrade | Odeon | Buy → Hold |
| 2022-05-27 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-03-28 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2022-03-07 | Downgrade | Jefferies | Buy → Hold |
| 2022-03-03 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2022-03-03 | Downgrade | Keefe Bruyette | Outperform → Mkt Perform |
| 2021-12-15 | Aggiornamento | Odeon | Hold → Buy |
| 2021-12-10 | Ripresa | UBS | Neutral |
| 2021-12-06 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-07 | Ripresa | Keefe Bruyette | Outperform |
| 2021-06-16 | Reiterato | Credit Suisse | Outperform |
| 2021-04-05 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2021-03-29 | Downgrade | Edward Jones | Buy → Hold |
| 2021-01-21 | Downgrade | Berenberg | Buy → Hold |
| 2021-01-06 | Iniziato | Daiwa Securities | Buy |
| 2021-01-04 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-11-19 | Aggiornamento | Keefe Bruyette | Mkt Perform → Outperform |
| 2020-10-15 | Downgrade | DZ Bank | Buy → Hold |
| 2020-10-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-08-18 | Downgrade | Odeon | Hold → Sell |
| 2020-07-17 | Downgrade | Odeon | Buy → Hold |
| 2020-07-08 | Iniziato | Seaport Global Securities | Buy |
| 2020-07-07 | Aggiornamento | Societe Generale | Hold → Buy |
| 2020-06-09 | Downgrade | Standpoint Research | Buy → Hold |
| 2020-06-02 | Aggiornamento | Odeon | Hold → Buy |
| 2020-05-18 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2020-04-20 | Aggiornamento | Argus | Hold → Buy |
| 2020-04-14 | Aggiornamento | Societe Generale | Sell → Hold |
| 2020-04-01 | Downgrade | Keefe Bruyette | Outperform → Mkt Perform |
| 2020-02-03 | Downgrade | Odeon | Buy → Hold |
| 2020-01-09 | Iniziato | DA Davidson | Buy |
| 2020-01-06 | Downgrade | Deutsche Bank | Buy → Hold |
| 2020-01-06 | Reiterato | Goldman | Buy |
| 2019-07-26 | Aggiornamento | Keefe Bruyette | Mkt Perform → Outperform |
| 2019-05-30 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-02-22 | Aggiornamento | Jefferies | Hold → Buy |
Mostra tutto
Citigroup Inc Borsa (C) Ultime notizie
SIG Maintained by Citigroup -- Price Target Raised to $140 - GuruFocus
Sana Biotechnology at citigroup’s biopharma back to school summit 2026: diabetes push - Investing.com
BioMarin at Citi summit: voxzogo drives growth as pipeline widens By Investing.com - Investing.com Canada
Olema Oncology at citigroup summit: palazestrant data, delays By Investing.com - Investing.com India
SYK Maintained by Citigroup -- Price Target Lowered to $360 - GuruFocus
Transcript : Novavax, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-10-2026 10 - marketscreener.com
Kymera Therapeutics at citigroup summit: oral immunology push gains pace By Investing.com - Investing.com India
SpyGlass Pharma at Citigroup summit: glaucoma lens nears phase iii By Investing.com - Investing.com Canada
SAB BIO at Citi summit: trial progress and a bigger t1d bet - Investing.com India
Jazz Pharmaceuticals at citigroup summit: rare-disease push gains pace By Investing.com - Investing.com India
Roivant at Citi summit: cash-rich biotech leans on three pillars - Investing.com Canada
MercadoLibre Secures $1.0 Billion 5.850% Notes Due 2036 With BofA, Citi, Goldman and Others - TradingView
Form 424B2 CITIGROUP INC - StreetInsider
Acumen at Citi biopharma summit: bets on oligomers and brain delivery - Investing.com
C Pushes Tokenized Deposits Deeper Into Asia With Japan Expansion - TradingView
Citigroup Inc. stock gains as recent earnings beat expectations - ad-hoc-news.de
Why Is Citigroup (NYES:C) Expanding in China Brokerage? - Kalkine Media
Citigroup (C) Gains on Turnaround Momentum - Yahoo Finance
Citigroup Adjusts Price Target on Cooper to $60 From $80, Keeps Neutral Rating - marketscreener.com
4 Thriving Investment Bank Behemoths to Buy With Attractive Valuation - TradingView
Form 8K Citigroup For: 10 September By Investing.com - Investing.com UK
Citigroup Upgrades UiPath (NYSE:PATH) to "Strong-Buy" - MarketBeat
Nordnet AB And Citigroup Inc. Launch Research Portal Giving Savers Access To Research - marketscreener.com
Citigroup Inc. $C Shares Acquired by Tidal Investments LLC - MarketBeat
Citigroup Adjusts Price Target on Boston Scientific to $57 From $61, Keeps Buy Rating - marketscreener.com
Citigroup Adjusts Price Target on ResMed to $240 From $235, Keeps Neutral Rating - marketscreener.com
Citigroup Inc. $C Position Trimmed by National Pension Service - MarketBeat
WINTON GROUP Ltd Has $11.44 Million Holdings in Citigroup Inc. $C - MarketBeat
Integrated Wealth Concepts LLC Sells 10,009 Shares of Citigroup Inc. $C - MarketBeat
Engineers Gate Manager LP Lowers Stake in Citigroup Inc. $C - MarketBeat
BlueCrest Capital Management Ltd Reduces Holdings in Citigroup Inc. $C - MarketBeat
Citigroup stock heads into the open after a 1.0 percent gain - ad-hoc-news.de
Citigroup Becomes Substantial Shareholder in Lotus Resources with 5.08% Stake - Kalkine
BioAge at Citi biopharma summit: pivot to eye disease and new targets - Investing.com Canada
Citigroup's Private Bank Hires Radzinski From Bank Of America - marketscreener.com
Veradermics at citigroup summit: oral hair-loss drug nears key data - Investing.com
Citi Private Bank hires Radzinski from Bank of America - WTVB
Akamai Technologies Jumps 5.3% After Citigroup Maintains Neutral - AlphaStreet
Transcript : Cytokinetics, Incorporated Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 03:00 PM - marketscreener.com
Beam Therapeutics at Citi summit: platform gains momentum across pipeline By Investing.com - Investing.com Canada
Citigroup : Citi First Quarter, Second Quarter, Third Quarter and Fourth Quarter 2027 Earnings Calls - marketscreener.com
PII Maintained by Citigroup -- Price Target Lowered to $67 - GuruFocus
Cytokinetics at citigroup summit: hcm expansion drives growth hopes By Investing.com - Investing.com India
Transcript : Protagonist Therapeutics, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 10 - marketscreener.com
Transcript : Beam Therapeutics Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 01 - marketscreener.com
Lexicon Pharmaceuticals at Citi summit: hcm data, t1d reset - Investing.com
Transcript : Spyre Therapeutics, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 10 - marketscreener.com
Ollie’s Bargain Outlet Holdings Drops 5.7% After Citigroup Maintains Buy - AlphaStreet
Learn Why The Bull Case For Citi Stock Could Change Following China Brokerage Approval - simplywall.st
Transcript : BioAge Labs, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 11 - marketscreener.com
Vor Biopharma at Citigroup’s biopharma back to school summit: pipeline push By Investing.com - Investing.com Canada
Citigroup Inc Azioni (C) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.34%
0.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):